Abstract Search

ey0018.2-10 | Neonatal diabetes mellitus | ESPEYB18

2.10. NKX2-2 mutation causes congenital diabetes and infantile obesity with paradoxical glucose-induced ghrelin secretion.

A Auerbach , A Cohen , N Ofek Shlomai , A Weinberg-Shukron , S Gulsuner , MC King , R Hemi , E Levy-Lahad , A Abulibdeh , D Zangen

J Clin Endocrinol Metab. 2020 Nov 1;105(11):dgaa563. doi: 10.1210/clinem/dgaa563. PMID: 32818257.This manuscript describes an unusual case of a baby born with a homozygous Nkx2.2 mutation who developed severe neonatal diabetes mellitus and then on follow up went onto develop severe obesity characterized by marked hyperphagia.Nkx2.2 is an important transcription factor...

0 shares

ey0017.11-12 | Pharmacologic Treatment | ESPEYB17

11.12. A randomized, controlled trial of liraglutide for adolescents with obesity

AS Kelly , P Auerbach , M Barrientos-Perez , I Gies , PM Hale , C Marcus , LD Mastrandrea , N Prabhu , S; NN8022-4180 Trial Investigators Arslanian

To read the full abstract: N Engl J Med. 2020;382(22):21172128. doi: https://pubmed.ncbi.nlm.nih.gov/32233338/Kelly et al. randomly assigned (1:1) n =251 obese adolescents (age 12 to <18 years) to receive either liraglutide (3.0 mg), a long-acting glucagon-like peptide-1 agonist, or placebo subcutaneously once daily in addition to lifestyle therapy. Liraglutide w...

2 shares

ESPE Yearbook of Paediatric Endocrinology

2.10. NKX2-2 mutation causes congenital diabetes and infantile obesity with paradoxical glucose-induced ghrelin secretion.

11.12. A randomized, controlled trial of liraglutide for adolescents with obesity

BiosciAbstracts